12:00 AM
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zymafos palifosfamide: Phase II started

Ziopharm began a 2-part, open-label, U.S. Phase II trial to evaluate Ad-RTS-IL-12 plus palifosfamide in up to 68 patients with visible lesions or lesions accessible by injection. The first part will consist of a safety run-in arm for Ad-RTS-IL-12 and palifosfamide as monotherapy or in combination. The second part...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >